Collagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have
Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical
ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are
genedrive plc (LON:GDR) is a commercial-stage company focused on point-of-care/need molecular diagnostics and biomarkers. Its Genedrive® in vitro diagnostic testing platform is at the forefront of this technology, offering a
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have been achieved in
Evgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways
Non-Standard Finance Plc (LON:NFS) Capital Markets day provided investors with a lot of detailed information on the business and highlighted three key themes. The detail is available from the presentation
Jatropha curcas, traditionally an undomesticated hedging plant with secondary utility as a source of oil, came to prominence when it was proposed as a feedstock for biofuel during an earlier
Until 2016, the only meaningful way to invest in listed housing was Grainger Trust or specialist student funds. Since November 2016, with Civitas Social Housing floating its over-subscribed REIT, £1,282m
600 Group Plc (LON:SIXH) is competitively well-positioned with a world class reputation. Business momentum is healthy with growth enhanced by new product launches and new market entry. Cyclicality is being
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
